In Silico Design, Synthesis, and Assays of Specific Substrates for Proteinase 3: Influence of Fluorogenic and Charged Groups

2014 ◽  
Vol 57 (3) ◽  
pp. 1111-1115 ◽  
Author(s):  
Shailesh Narawane ◽  
Adnan Budnjo ◽  
Cédric Grauffel ◽  
Bengt Erik Haug ◽  
Nathalie Reuter
Keyword(s):  
In Silico ◽  
Proteinase 3 ◽  
Design Synthesis ◽  
In Silico Design

In silico design, synthesis, characterization and pharmacological evaluation of captopril conjugates in the treatment of renal fibrosis

2019 ◽  
Vol 43 (1) ◽  
pp. 504-513 ◽  
Author(s):  
Swapnil Dashrath Jadhav ◽  
Prafulla Balkrishna Choudhari ◽  
Manish Sudesh Bhatia
Keyword(s):  
Glutamic Acid ◽  
In Silico ◽  
Renal Fibrosis ◽  
Design Synthesis ◽  
In Silico Design ◽  
Pharmacological Evaluation ◽  
P Application

Application of glutamic acid and taurine conjugates of captopril for kidney targeting.

In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents

2019 ◽  
Vol 83 ◽  
pp. 107156 ◽  
Author(s):  
Sudhan Debnath ◽  
Manupati Kanakaraju ◽  
Minarul Islam ◽  
Ragini Yeeravalli ◽  
Debanjan Sen ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
In Silico ◽  
Egfr Inhibitors ◽  
Potential Drug ◽  
Design Synthesis ◽  
In Silico Design

In Silico Design, Synthesis and Bioactivity of N-(2, 4-Dinitrophenyl)-3-oxo- 3-phenyl-N-(aryl) Phenyl Propanamide Derivatives as Breast Cancer Inhibitors

2017 ◽  
Vol 13 (2) ◽  
pp. 112-126 ◽  
Author(s):  
Mucheli Ramana ◽  
Rama Lokhande ◽  
Shanta Bhar ◽  
Prasanna Ranade ◽  
Ankita Mehta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Silico ◽  
Design Synthesis ◽  
In Silico Design

Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology

RSC Advances ◽  
2016 ◽  
Vol 6 (31) ◽  
pp. 26003-26018 ◽  
Author(s):  
Dhanaraju Mandalapu ◽  
Deependra Kumar Singh ◽  
Sonal Gupta ◽  
Vishal M. Balaramnavar ◽  
Mohammad Shafiq ◽  
...  
Keyword(s):  
In Silico ◽  
Pharmacophore Model ◽  
Dna Ligase ◽  
Design Synthesis ◽  
In Silico Design ◽  
Human Dna ◽  
Dna Ligase I

A pharmacophore model identified a novel class of hLigI inhibitors to treat cancer. 36 compounds were synthesized and the identified inhibitor, compound 23 shown antiligase activity at IC50 24.9 μM by abolishing the interaction between hLigI and DNA.

Sign in / Sign up

Export Citation Format

Share Document